![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (OCT) Formulation in Children 6-11 Years
|
|
|
Reported by Jules Levin
CROI 2010 Feb 16-19 SF
Sharon Nachman , Edward Acosta, Pearl Samson, Hedy Teppler, Brenda Homony, Terence Fenton, Edward Handelsman, Carol Worrell, Bobbie Graham, Andrew Wiznia, and The P1066 Group
![image002.gif](../images/022010/image002.gif)
![image004.gif](../images/022010/image004.gif)
![image006.gif](../images/022010/image006.gif)
![image008.gif](../images/022010/image008.gif)
![image010.gif](../images/022010/image010.gif)
![image012.gif](../images/022010/image012.gif)
![image014.gif](../images/022010/image014.gif)
![image016.gif](../images/022010/image016.gif)
![image018.gif](../images/022010/image018.gif)
![image020.gif](../images/022010/image020.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|